Over the last two decades, several attempts to generate packaging cells for lentiviral vectors (LV) have been made. Despite different technologies, no packaging clone is currently employed in clinical trials. We developed a new strategy for LV stable production based on the HEK-293T progenitor cells; the sequential insertion of the viral genes by integrating vectors; the constitutive expression of the viral components; and the RD114-TR envelope pseudotyping. We generated the intermediate clone PK-7 expressing constitutively gag/pol and rev genes and, by adding tat and rd114-tr genes, the stable packaging cell line RD2-MolPack, which can produce LV carrying any transfer vector (TV). Finally, we obtained the RD2-MolPack-Chim3 producer clone by transducing RD2-MolPack cells with the TV expressing the anti-HIV transgene Chim3. Remarkably, RD114-TR pseudovirions have much higher potency when produced by stable compared with transient technology. Most importantly, comparable transduction efficiency in hematopoietic stem cells (HSC) is obtained with 2-logs less physical particles respect to VSV-G pseudovirions produced by transient transfection. Altogether, RD2-MolPack technology should be considered a valid option for large-scale production of LV to be used in gene therapy protocols employing HSC, resulting in the possibility of downsizing the manufacturing scale by about 10-fold in respect to transient technology.
Stornaiuolo and colleagues describe a packaging cell line for the stable production of clinical-grade lentiviral vectors for anti-HIV gene therapy. Pseudovirions generated using this cell line are able to transduce a higher proportion of progenitor CD34+ stem cells as compared with vesicular stomatitis virus glycoprotein (VSV-G) pseudovirions.
Get full access to this article
View all access options for this article.
References
1.
BahnerI., SumiyoshiT., KagodaM.et al.2007. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther., 15:76–85.
2.
BestorT.H.2000. Gene silencing as a threat to the success of gene therapy. J. Clin. Invest., 105:409–411.
3.
BovolentaC., PorcelliniS., AlbericiL.2012. Therapeutic genes for Anti-HIV/AIDS Gene Therapy. Curr. Pharm. Biotechnol.[Epub ahead of print]
4.
BrandtnerE.M., KodajovaP., KnappE.et al.2008. Quantification and characterization of autotransduction in retroviral vector producer cells. Hum. Gene Ther., 19:97–102.
5.
BroussauS., JabbourN., LachapelleG.et al.2008. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol. Ther., 16:500–507.
6.
BurnsJ.C., FriedmannT., DrieverW.et al.1993. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. U. S. A., 90:8033–8037.
7.
CarrollR., LinJ.T., DacquelE.J.et al.1994. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J. Virol., 68:6047–6051.
8.
CheungA.K., HogganM.D., HauswirthW.W., BernsK.I.1980. Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J. Virol., 33:739–748.
9.
CockrellA.S., MaH., FuK.et al.2006. A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol. Ther., 14:276–284.
10.
CorbeauP., KrausG., Wong-StaalF.1996. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc. Natl. Acad. Sci. U. S. A., 93:14070–14075.
Di NunzioF., PiovaniB., CossetF.L.et al.2007. Transduction of human hematopoietic stem cells by lentiviral vectors pseudotyped with the RD114-TR chimeric envelope glycoprotein. Hum. Gene Ther., 18:811–820.
13.
FarsonD., WittR., McGuinnessR.et al.2001. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum. Gene Ther., 12:981–997.
14.
GreenB.J., LeeC.S., RaskoJ.E.2004. Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. J. Gene Med., 6:249–259.
15.
HanawaH., PersonsD.A., NienhuisA.W.2005. Mobilization and mechanism of transcription of integrated self-inactivating lentiviral vectors. J. Virol., 79:8410–8421.
KafriT., Van PraagH., OuyangL.et al.1999. A packaging cell line for lentivirus vectors. J. Virol., 73:576–584.
18.
KaplanA.H., SwanstromR.1991. The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed. Biochim. Acta, 50:647–653.
19.
KaulM., YuH., RonY., DoughertyJ.P.1998. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology, 249:167–174.
20.
KimY.S., WielgoszM.M., HargroveP.et al.2010. Transduction of human primitive repopulating hematopoietic cells with lentiviral vectors pseudotyped with various envelope proteins. Mol. Ther., 18:1310–1317.
KlagesN., ZuffereyR., TronoD.2000. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol. Ther., 2:170–176.
23.
KotinR.M., SiniscalcoM., SamulskiR.J.et al.1990. Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. U. S. A., 87:2211–2215.
24.
KotinR.M., MenningerJ.C., WardD.C., BernsK.I.1991. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics, 10:831–834.
25.
KotinR.M., LindenR.M., BernsK.I.1992. Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J., 11:5071–5078.
26.
KrausslichH.G.1992. Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J. Virol., 66:567–572.
27.
KrausslichH.G., OchsenbauerC., TraencknerA.M.et al.1993. Analysis of protein expression and virus-like particle formation in mammalian cell lines stably expressing HIV-1 gag and env gene products with or without active HIV proteinase. Virology, 192:605–617.
28.
LaaksoM.M., SuttonR.E.2006. Replicative fidelity of lentiviral vectors produced by transient transfection. Virology, 348:406–417.
29.
LamartinaS., SporenoE., FattoriE., ToniattiC.2000. Characteristics of the adeno-associated virus preintegration site in human chromosome 19: open chromatin conformation and transcription-competent environment. J. Virol., 74:7671–7677.
30.
MaruggiG., PorcelliniS., FacchiniG.et al.2009. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther., 17:851–856.
MusatovS.A., DudusL., ParrishC.M.et al.2002. Spontaneous mobilization of integrated recombinant adenoassociated virus in a cell culture model of virus latency. Virology, 294:151–169.
33.
NakaiH., IwakiY., KayM.A., CoutoL.B.1999. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J. Virol., 73:5438–5447.
34.
NeffT., PetersonL.J., MorrisJ.C.et al.2004. Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells. Mol. Ther., 9:157–159.
35.
NiY., SunS., OparaochaI.et al.2005. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J. Gene Med., 7:818–834.
36.
PacchiaA.L., AdelsonM.E., KaulM.et al.2001. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology, 282:77–86.
37.
PoeschlaE., CorbeauP., Wong-StaalF.1996. Development of HIV vectors for anti-HIV gene therapy. Proc. Natl. Acad. Sci. U. S. A., 93:11395–11399.
38.
PorcelliniS., AlbericiL., GubinelliF.et al.2009. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Blood, 113:3443–3452.
39.
PorcelliniS., GubinelliF., AlbericiL.et al.2010. Chim3 confers survival advantage to CD4+T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay. Blood, 115:4021–4029.
40.
RecchiaA., PeraniL., SartoriD.et al.2004. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther., 10:660–670.
41.
SamulskiR.J., ChangL.S., ShenkT.1987. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol., 61:3096–3101.
42.
SandrinV., BosonB., SalmonP.et al.2002. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood, 100:823–832.
43.
SandrinV., MuriauxD., DarlixJ.L., CossetF.L.2004. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses. J. Virol., 78:7153–7164.
44.
SnaselJ., ShoemanR., HorejsiM.et al.2000. Cleavage of vimentin by different retroviral proteases. Arch. Biochem. Biophys., 377:241–245.
45.
SparacioS., PfeifferT., SchaalH., BoschV.2001. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol. Ther., 3:602–612.
46.
SrinivasakumarN., ChazalN., Helga-MariaC.et al.1997. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol., 71:5841–5848.
47.
StrangB.L., IkedaY., CossetF.L.et al.2004. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther., 11:591–598.
48.
ThromR.E., OumaA.A., ZhouS.et al.2009. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood, 113:5104–5110.
49.
TrobridgeG.D., WuR.A., HansenM.et al.2010. Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. Mol. Ther., 18:725–733.
50.
VogtB., RoscherS., AbelB.et al.2001. Lack of superinfection interference in retroviral vector producer cells. Hum. Gene Ther., 12:359–365.
51.
XuK., MaH., McCownT.J.et al.2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol. Ther., 3:97–104.
52.
YuH., RabsonA.B., KaulM.et al.1996. Inducible human immunodeficiency virus type 1 packaging cell lines. J. Virol., 70:4530–4537.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
